StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) stock

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1415.55−16.12 (-1.13%)

Close on Nov 17, 2026Market cap $1.33TP/E 45.9Yield 0.44%

Eli Lilly total assets

Total assets on the balance sheet at the end of each period.

Eli Lilly's total assets was $148.07B at Sep 30, 2026. For fiscal 2025 it was $112.48B, up 42.9% from the year before. Over ten years it grew 12.2% a year on average. The highest annual figure on record is $112.48B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$112.48B+42.9%
FY2024Dec 31, 2024$78.72B+23.0%
FY2023Dec 31, 2023$64.01B+29.3%
FY2022Dec 31, 2022$49.49B+1.4%
FY2021Dec 31, 2021$48.81B+4.7%
FY2020Dec 31, 2020$46.63B+18.7%
FY2019Dec 31, 2019$39.29B-10.5%
FY2018Dec 31, 2018$43.91B-2.4%
FY2017Dec 31, 2017$44.98B+15.9%
FY2016Dec 31, 2016$38.81B+9.1%
FY2015Dec 31, 2015$35.57B-2.0%
FY2014Dec 31, 2014$36.31B+3.0%
FY2013Dec 31, 2013$35.25B+2.5%
FY2012Dec 31, 2012$34.40B+2.2%
FY2011Dec 31, 2011$33.66B+8.6%
FY2010Dec 31, 2010$31.00B+12.9%
FY2009Dec 31, 2009$27.46B-6.0%
FY2008Dec 31, 2008$29.21B–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$148.07B+28.8%
Q2 FY2026Jun 30, 2026$142.28B+41.0%
Q1 FY2026Mar 31, 2026$116.58B+30.4%
Q4 FY2025Dec 31, 2025$112.48B+42.9%
Q3 FY2025Sep 30, 2025$114.94B+52.0%
Q2 FY2025Jun 30, 2025$100.92B+40.4%
Q1 FY2025Mar 31, 2025$89.39B+39.8%
Q4 FY2024Dec 31, 2024$78.72B+23.0%
Q3 FY2024Sep 30, 2024$75.61B+30.5%
Q2 FY2024Jun 30, 2024$71.87B+31.1%
Q1 FY2024Mar 31, 2024$63.94B+20.3%
Q4 FY2023Dec 31, 2023$64.01B+29.3%
Q3 FY2023Sep 30, 2023$57.92B+22.0%
Q2 FY2023Jun 30, 2023$54.81B+16.5%
Q1 FY2023Mar 31, 2023$53.16B+13.3%
Q4 FY2022Dec 31, 2022$49.49B+1.4%
Q3 FY2022Sep 30, 2022$47.46B-1.5%
Q2 FY2022Jun 30, 2022$47.06B-1.6%
Q1 FY2022Mar 31, 2022$46.92B+0.2%
Q4 FY2021Dec 31, 2021$48.81B+4.7%
Q3 FY2021Sep 30, 2021$48.19B+9.7%
Q2 FY2021Jun 30, 2021$47.81B+13.9%
Q1 FY2021Mar 31, 2021$46.84B+14.0%
Q4 FY2020Dec 31, 2020$46.63B+18.7%
Q3 FY2020Sep 30, 2020$43.95B+16.0%
Q2 FY2020Jun 30, 2020$41.97B+8.5%
Q1 FY2020Mar 31, 2020$41.10B+8.1%
Q4 FY2019Dec 31, 2019$39.29B-10.5%
Q3 FY2019Sep 30, 2019$37.89B-15.1%
Q2 FY2019Jun 30, 2019$38.67B-8.7%
Q1 FY2019Mar 31, 2019$38.01B-14.3%
Q4 FY2018Dec 31, 2018$43.91B-2.4%
Q3 FY2018Sep 30, 2018$44.63B+3.8%
Q2 FY2018Jun 30, 2018$42.36B+3.5%
Q1 FY2018Mar 31, 2018$44.36B+17.9%
Q4 FY2017Dec 31, 2017$44.98B+15.9%
Q3 FY2017Sep 30, 2017$43.01B–
Q2 FY2017Jun 30, 2017$40.95B–
Q1 FY2017Mar 31, 2017$37.62B–
Q4 FY2016Dec 31, 2016$38.81B–

More Eli Lilly figures

See a number that looks wrong?